1. Pink Sheet

Revising Adult RSV Policy: US CDC Moves Toward Risk-Based Vaccine Recommendation

 
• By Bridget Silverman

The unpopular shared clinical decision-making policy for RSV vaccines in adults age 60 and older should be replaced by risk-based criteria in people age 60-74 and a universal age-based recommendation at 75 and older, the CDC’s Advisory Committee on Immunization Practices agrees.

RSV Vaccine
The ACIP work group said to recommend GSK's RSV vaccine for adults age 60-74 at increased risk of severe disease. • Source: Shutterstock

One year after the US Centers for Disease Control and Prevention issued its first recommendations for adult respiratory syncytial virus vaccines, its Advisory Committee for Immunization Practices agreed to move away from the unwieldy original shared clinical decision-making policy in favor of a combination of a risk-based and age-based recommendations.

Key Takeaways

  • The CDC’s Advisory Committee on Immunization Practices revisited its adult respiratory syncytial virus vaccine recommendations, unanimously voting to change the year-old shared clinical decision-making recommendation for people 75 and older.

  • ACIP agreed on a universal recommendation for adults 75 and older and a risk-based recommendation for adults age 60-74 at increased risk for severe RSV disease

The ACIP voted 11-0 on 26 June in favor of a universal recommendation that adults 75 years of age and older should receive an RSV vaccine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.